ADR Biomedical Holdings (TSE:3750) Research & Development: 円0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:3750 ADR Biomedical Holdings Inc TSE:3750
24 GF Score
Price 円763.00
GF Value 円39.23
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is ADR Biomedical Holdings Research & Development?

ADR Biomedical Holdings TSE:3750 -0.13% 24 Research & Development is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:3750 with a GF Score™ of 24/100 and a GF Value™ of 円39.23 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ADR Biomedical Holdings's Research & Development for the three months ended in Mar. 2026 was 円0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.0 Mil.

ADR Biomedical Holdings  (TSE:3750) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ADR Biomedical Holdings Research & Development Related Terms

ADR Biomedical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for ADR Biomedical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADR Biomedical Holdings Research & Development Chart

ADR Biomedical Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 145.24 351.35 202.95 153.28

ADR Biomedical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:3750
24GF Score
ADR Biomedical Holdings Inc TSE:3750
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADR Biomedical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円0.0 Mil mean?
ADR Biomedical Holdings (TSE:3750) has a Research & Development of 円0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ADR Biomedical Holdings and its competitors.
Is ADR Biomedical Holdings' Research & Development too high?
ADR Biomedical Holdings' current Research & Development is 円0.0 Mil. Overall, ADR Biomedical Holdings has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Research & Development compare to VRTX and REGN?
ADR Biomedical Holdings' Research & Development of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ADR Biomedical Holdings and its competitors. ADR Biomedical Holdings's current Research & Development is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.23, compared to a current price of 円763.00 — trading 1844.9% above its estimated fair value. The current Research & Development is 円0.0 Mil. ADR Biomedical Holdings' overall GF Score™ is 24/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Research & Development is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?

Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued. The current stock price of 円763.00 is trading 1844.9% above its estimated GF Value™ of 円39.23. GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.

Key valuation signals for TSE:3750:

  • Research & Development: 円0.0 Mil
  • GF Value™: 円39.23 vs. price of 円763.00 (1844.9% above fair value)
  • GF Score™: 24/100 with 8 warning signs

No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADR Biomedical Holdings Business Description

Address 1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
24GF Score

Get the complete analysis for TSE:3750

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円763.00
Price
円39.23
GF Value